{"denoms":[{"counts":[{"groupId":"BG000","value":"335"},{"groupId":"BG001","value":"337"},{"groupId":"BG002","value":"672"}],"units":"Participants"}],"groups":[{"description":"Ribociclib 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)","id":"BG000","title":"Ribociclib + NSAI/Tamoxifen + Goserelin"},{"description":"Placebo daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days).\n\nParticipants were unblinded once the final OS analysis was conducted and after the implementation of protocol amendment 6 (16-Jul-2019) and were given the option to crossover to treatment with ribociclib +NSAI/tamoxifen + goserelin","id":"BG001","title":"Placebo + NSAI/Tamoxifen+ Goserelin"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.6","value":"42.6"},{"groupId":"BG001","spread":"6.17","value":"43.7"},{"groupId":"BG002","spread":"6.4","value":"43.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"335"},{"groupId":"BG001","value":"337"},{"groupId":"BG002","value":"672"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"187"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"388"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"198"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"19"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}],"title":"Native American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"23"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"38"}]}],"title":"Unknown"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}